摘要
Abstract
OBJECTIVE: To observe the clinical efficacy of large-dose of cytosine arabinoside (Ara-C) in the treatment of children acute lymphoblastic leukemia (ALL). METHODS: 50 ALL patients were collected from our hospital during Nov. 2003 to Nov. 2006 and then divided into treatment group and control group. After the patients achieved complete remission by receiving conventional induction chemotherapy program, the treatment group received consolidation therapy of HD (H means homoharringto-nine; D means daunomycin) combined with large-dose of Ara-C, and the control group received consolidation therapy of HD alone. Clinical efficacies of 2 groups were observed and compared, and the disease free survival (DFS) of 2 groups in 1 year, 3 years and 5 years after chemotherapy were observed as well as adverse drug reactions. RESULTS: The total effective rate of treatment group was 88.0%, which was significantly higher than that of control group (44.0%), there was statistical significance (X2= 4.399, P<0.05); the DFS of treatment group in 1 year, 3 years and 5 years was 88.0%, 64.0% and 32.0%, and those of control group were 48.0%, 20.0% and 0, respectively. Those of treatment group were all higher than those of control group (X2=4.116, 5.439, 6.821, P<0.05); bone marrow suppression and gastrointestinal tract reaction at different degrees were observed in both groups during chemotherapy, but the adverse drug reactions of 2 groups was not statistically significant (P>0.05). CONCLUSION: The consolidation therapy of large-dose of Ara-C has good clinical efficacy and safety in the treatment of pediatric ALL, and can significantly prolong the DFS.关键词
阿糖胞苷/急性淋巴细胞白血病/儿童/临床疗效/不良反应Key words
Cytosine arabinoside/ Acute lymphoblastic leukemia/ Children/ Clinical efficacy/ Adverse drug reactions
分类
医药卫生
